Introduction
In recent decades, the etiology of aortic stenosis (AS) has fundamentally evolved to be predominantly 'degenerative' in origin. 1 Calcification is the dominant mechanism of progressive aortic valve obstruction in the majority of elderly patients with severe AS. 2, 3 Nonetheless, in some cases patients with low calcification are diagnosed with haemodynamically severe AS. The prevalence, mechanism of valve stenosis, and implications of low AVC severe AS remain unclear. Recent studies that have evaluated aortic valve calcification (AVC) with CT scans have found different cut-points for men and women that strongly correlate with both haemodynamic assessment of stenosis severity and with excess mortality. 4, 5 Transcatheter aortic valve implantation (TAVI) has emerged as a treatment option for inoperable or high-risk surgical patients with severe AS. 6, 7 Increased AVC has been associated to increased paravalvular regurgitation (PVR) and higher frequency of postdilatation following TAVI. [8] [9] [10] On the other hand, milder degree of aortic valve calcification has been associated with valve embolization following selfexpandable TAVI. 11 Nonetheless, short-term outcomes of balloonexpandable TAVI in patients with mildly calcified aortic valves and severe AS have not been previously described.
The purpose of the present study was to evaluate the clinical and haemodynamic characteristics as well as the outcome of patients with severe aortic stenosis and low AVC that undergo TAVI.
Methods
We retrospectively examined 563 patients with severe symptomatic AS that underwent balloon-expandable TAVI during a 3 year period at our institute. All patients had congestive heart failure with New-York Heart Association (NYHA) class II-IV symptoms. All underwent preprocedural coronary angiography to assess the need of revascularization. Aortic valve disease was assessed with transthoracic echocardiography performed by experienced echocardiographers. Evaluation of AS severity was performed based on peak velocity, mean gradient and calculation of the aortic valve area (AVA) using the continuity equation as recommended by current guidelines. 12 All patients had an AVA of <1 cm 2 Patients were also evaluated by an ECG-gated, multi-slice CT angiography study with a Siemens Somatom Cardiac 64 scanner or a Siemens Somatom Flash scanner (Siemens Medical Solutions USA Inc., Malvern, Pennsylvania). Aortic valve calcium was quantified by a standard Agatston methodology for all available non-contrast CT scans, with a threshold for calcium detection set at 130 Hounsfield Units (HU) and 3-mm slice thickness. 13 It was performed offline on dedicated workstations with validated software (Vitrea Software; Vital Images, Inc., Minnetonka, MN, USA). The aortic valve was visualized in multiple planes, and careful measurement section by section aimed to accurately exclude contiguous calcium in coronary arteries, mitral valve annulus, or aortic wall. A region of interest for calcium quantification was made from approximately 3 mm below the basal annular plane to the leaflet tips. Based on a previous study by Clavel et al., 4 patients that had aortic valve calcification score (AVCS) of < _1274 Agatston units (AU) for women and < _2065 for men were compared to patients with higher calcification scores ( Figure 1 , see Supplementary data online, Online Movie S1). From a repeated measurement for a subset of 20 randomly selected patients, intra-and inter-observer variability for AVCS was excellent (intra-observer: intraclass correlation coefficient: 0.99, P < 0.001; interobserver: intraclass correlation coefficient: 0.99, P < 0.001). Prosthetic valve size selection was based mainly on pre-TAVR contrast CT. Pre-procedural three-dimensional transoesophageal echocardiography was used in patients having relative contra-indications to contrast CT (e.g. patients with renal failure). TAVI over/under sizing (coverage index) was defined as (bioprosthetic valve area/CT annulus area)-1*100. TAVI was performed under general anesthesia in all cases. The vascular access approach was chosen on the basis of the individual patient's risk profile. All patients were considered high risk for valve surgery by our institutional heart team. : cut-point specifically tested and validated for the hybrid AVA with outcome data. 15 Baseline clinical, echocardiographic, and procedural details for TAVI were recorded for all patients including 1 month clinical and echocardiographic assessments during a follow-up visit. TAVI endpoints, device success and adverse events were considered according to the Valve Academic Research Consortium (VARC)-2 definitions. 16 Post TAVI PVR was assessed in line with VARC-2 criteria with periprocedural transoesophageal echocardiography examinations reviewed retrospectively. This was performed by one of the physician readers experienced in the assessment of TAVI echocardiograms, blinded to the clinical data. The study was approved by the institutional review board (IRB) and informed consent was obtained from all subjects.
Statistical analysis
Continuous variables were tested for distribution normality with the Shapiro-Wilk test and expressed as mean ± SD or median and interquartile range. These variables were compared using 2-sided student's t-test or Wilcoxon rank sum test, as appropriate. Categorical variables are expressed as number (percentage) and were compared using the Pearson v 2 test or Fisher exact test, as appropriate. KaplanMeier survival curves were compared according to AVCS (low vs. high), mean aortic valve gradient (low vs. high), flow (low vs. normal), LVEF (low vs. normal), and AS severity based on hybrid AVA (confirmed severe AS vs. reclassified moderate AS). Kaplan-Meier survival plot significance was estimated using the log-rank test. Cox multivariable regression analysis was performed to identify if low and high AVCS correlate independently with overall mortality. The multivariable model was built by selecting baseline and procedural variables that satisfied the entry criterion of P < 0.2 in a univariate analysis. In order to examine if low AVCS is independently associated with low rates of PVR, we performed a logistic regression analysis including mean annulus diameter, coverage index, access, and valve type. All of the analyses were considered significant at a two-tailed P value of less than 0.05. The SPSS statistical package, version 20.0 was used to perform all statistical evaluation (SSPS Inc. Chicago, IL, USA).
Results
Overall, 734 patients underwent balloon-expandable TAVI (Edwards Lifesciences, Irvine, CA), at our institute during the study period. We excluded from analysis 29 patients that had valve-in-valve implantations and 142 patients that did not have concurrent non-contrast CT scan available for analysis of AVCS. Of the remaining 563 patients, 93 patients had mild calcification (AVCS < _1274 AU for women and < _ 2065 AU for men) and 470 had higher calcification scores (mean AVCS: 1278 ± 485 vs. 4062 ± 2029 AU, respectively; P < 0.001). The baseline clinical patient characteristics and pre-TAVI imaging details of the study population are shown in Values are mean ± SD or n (%), or median (interquartile range). *Low calcification defined as AVCS < _ 1274 AU for women and < _2065 AU for men; High calcification defined as AVCS > 1274 AU for women and >2065 AU for men. a Creatinine clearance < 30 mL/min/m 2 . AU, Agatston units; AV, Aortic valve; AVCd, aortic valve calcification score indexed to the cross-sectional area of the aortic annulus; AVCS, aortic valve calcification score; AVA, aortic valve area; BMI, body mass index; BSA, body surface area; CAD, coronary artery disease; CABG, coronary artery bypass graft; PAD, peripheral artery disease; STS, Society of Thoracic Surgeons; TIA, transient ischaemic attack.
.
(P < 0.001) (Figure 2) . Overall, 50/563 patients (9%) had low AVCS and high-gradient severe AS (Figure 3) .
Procedural details are shown in Table 2 . Overall, the transfemoral approach was used in 85.1% of the cases, transapical approach in 4.8%, transaortic approach in 9.2%, and subclavian approach in 0.9%. Device success rate was 98.9% (92 of 93) for patients with low AVCS compared with 96% (451 of 470) for patients with high AVCS (P = 0.16). Total fluoroscopy time and total contrast used were similar between groups. There were significantly lower rates of postprocedural PVR in patients with low AVCS (> _mild PVR: 12.9% vs. 26 .6%; P = 0.03). It remained independently significant in a multivariate model including mean annulus diameter, coverage index, access (transfemoral vs. alternative access) and valve type (OR 0.42; 95% CI: 0.21-0.86; P = 0.02). SAPIEN 3 valve implantation was also found to be associated with lower rate of postprocedural PVR in this model (OR for > _mild PVR: 0.29; 95% CI: 0.17-0.51; P < 0.01). Patients in the low AVCS group had an average oversizing of 17.7 ± 13.3% compared to 12.9 ± 12.6% for patients in the high AVCS group (P = 0.002). Overall, there were only 3 cases of valve embolization, 2 (0.4%) among patients high AVCS and 1 (1.1%) among patients with low AVCS (P = 0.42).
There was 1 case (1.1%) of all-cause mortality up to 30-days in among patients with low AVCS and 13 cases in the rest of the patients (2.8%; P = 0.48). During a mean follow-up period of 12.6 ± 8.1 months there were 8 cases (8.6%) of mortality in the low AVCS group compared to 68 cases (14.5%) in patients with higher calcification scores (P = 0.13). Kaplan-Meier survival analysis was performed for both groups up to 18 months after TAVI. There was similar survival between the low and high AVCS groups (P = 0.26, log-rank test; Figure 4A ). Overall survival remained similar in a multivariable analysis including age, BMI, diabetes, chronic renal failure, LVEF, mean aortic valve gradient, mean annulus diameter, access and valve type (HR for mortality for the low AVCS group: 0.77; 95 CI:0.34- 1.74 ; P = 0.53). Sub-group comparison showed that patients with low AVCS and high aortic valve gradient had better survival and patients with high AVCS and LG had the worst survival (P = 0.017, log-rank test; Figure 4B ). With age adjustments these difference remained similar. Sub-group comparison also showed that patients with LVEF< 50% had worst survival compared to patients with higher LVEF (P = 0.02, log-rank test; Figure 4C ). Thirty-day complications, according to VARC-2 are elaborated in Table 3 . All major complication rates were similar between groups.
After excluding 43 patients that did not have contrast CT, 520 patients had hybrid AVA available for further analysis. Using a cut-point value of hybrid AVA > 1.0 cm Figure S1 ).
Discussion
Active calcification is prominent early in the disease process and is a major factor in the leaflet stiffness of severe AS. 3 High AVC assessed with CT is a powerful risk factor for mortality in patients with AS treated conservatively 5 and may also be used to differentiate between severe and non-severe AS. 17 While increased AVC has been associated with increased rate of PVR and of aortic rupture following TAVI, [8] [9] [10] 18 mild AVC have been suggested as a risk factor for valve embolization during this procedure. 11, 19 In the present study, we focused on patients with low AVCS and found that patients with low calcification that underwent TAVI were younger and had higher BMI compared to patient with higher degree of AVC. Overall, 9% of the entire cohort had high-gradient severe AS despite low calcification of the aortic valve. Performing balloon-expandable TAVI in patients with low AVC was associated with high device success and decreased rates of PVR. Short-term clinical outcomes and overall mortality were comparable to patients with higher AVCS including similar rate of valve embolization in patients with low calcification. Previous studies with CT have shown that AVC quantification is strongly but nonlinearly associated with haemodynamic measures of AS severity. 20, 21 AVCS measured by CT has been shown to be useful to differentiate severe vs. non-severe AS in patients with LF-LG AS as well as those with normal-flow, LG AS. 22 Moreover, Pibarot and Dumesnil recommended that quantification of valve calcification by CT may be used to corroborate stenosis severity in borderline/inconclusive cases. 17 Clavel et al. 4 provided sex-specific definitions for severe AVC load, with lower thresholds in women (men: 2065 AU; women: 1274 AU). In a recent study, these thresholds were found to be strongly related to excess mortality which is greatly alleviated by aortic valve replacement. 5 Interestingly, 50 out of the 93 patients (53.8%) with low AVCS had high gradient severe AS in the present study, and 36 out of the remaining 43 patients were found to have LF-LG AS that was determined to be severe by other modalities (e.g. dobutamine stress echocardiography). From our overall population of elderly patients with degenerative aortic valve disease that underwent TAVI, there were 50/563 patients (8.9%) with high-gradient severe AS and 36/563 patients (6.4%) with LF-LG severe AS despite low AVCS. The mechanism of valve stenosis in these non-rheumatic low calcified severe AS patients is yet to be determined but it cannot be attributed to calcium deposition which has been believed thus-far to be the hallmark and invariable pathogenesis of severe AS. 2, 3 This discrepancy between AVCS and the haemodynamic severity of AS could have been related to the fact that these patients may have relatively more fibrous or fibro-fatty, rather than calcific deposits in the aortic valve leaflets, which could also contribute to valve stenosis. Values are mean ± SD or n (%). *Low calcification defined as AVCS < _ 1274 AU for women and < _2065 AU for men; High calcification defined as AVCS > 1274 AU for women and >2065 AU for men. AU, Agatston units; AV, aortic valve; AVCS, aortic valve calcification score; PVR, paravalvular regurgitation; TEE, transoesophageal echocardiography.
Interestingly, we found that increased BMI and higher prevalence of diabetes mellitus is associated with low calcification among our patients. Lindroos et al. have previously demonstrated an inverse relation between BMI and AVC evaluated qualitatively with echocardiography. 23 On the other hand, Messika-Zeitoun et al.,
examined CT of 226 participants and demonstrated association between higher BMI and higher rates of AVC. 24 Calcification of the aortic valve is considered to be a fundamental characteristic of advanced AS and the severity of the calcification correlates with valve stenosis severity, disease progression, and the development of symptoms and adverse events. 3 The finding in the present study that a subset of patients with higher BMI and low AVCS are undergoing TAVI for severe symptomatic AS may suggest a different pathogenesis for the progression of AS in this subset of patients. PVR is an important complication of TAVI that is associated with increased mortality. 25 Several previous papers have demonstrated that AVC predicts PVR following both self-expandable and balloonexpandable TAVI. 8, 9, [26] [27] [28] [29] In a recent publication by our group, aortic valve leaflet calcium burden was found to be significant independent predictor of PVR after balloon-expandable TAVI. 8 Khalique et al. 9 showed that quantity and asymmetry of AVC in all regions of the aortic valve complex predict greater than or equal to mild PVR. Haensig et al. 26 demonstrated that AVC evaluation using Agatston scoring methodology was associated with increased PVR following transapical TAVI. In line with previous studies, we found that patients with low AVCS in our study had lower rates of > _mild PVR (OR 0.42; 95% CI: 0.21-0.86; P = 0.02). Calcification of the aortic valvular complex is important for proper anchoring of balloon-expandable transcatheter heart valves. 30 Van
Mieghem et al., compared 18 cases of valve dislodgment following self-expandable TAVI to 80 cases without this complication. 11 In a CT analysis of all patients, AVCS was 1951 AU in the valve dislodgment group vs. 3289 for the remaining cases (P = 0.016). Moreover, patients with an extremely low grade of aortic valve calcification are considered to be at increased risk for valve embolization during TAVI. 19, 30 In the present cohort of patients that underwent balloonexpandable TAVI, we had only 3 cases of valve embolization-1 of them among patients with low AVCS. A device success rate of 98.9% for the 93 patients with low AVCS is also encouraging. Two measures that may be used in order to decrease the risk of valve embolization in patients with extremely low AVC undergoing balloon-expandable TAVI are greater oversizing (17.7% vs. 12 .9% in the current study) and the addition of an incremental 1-2cc to the inflation balloon during valve deployment. Previous studies examining the correlation between AVC and clinical outcome following TAVI have yielded mixed results. [31] [32] [33] Leber et al. 31 found high calcification to be associated with 30-day death, (A) Kaplan-Meier curves for overall survival in patients according to reclassification (using hybrid AVA>1.0 cm 2 cut-point value) and aortic valve mean gradient (P = 0.102, log-rank test). (B) Kaplan-Meier curves for overall survival according to reclassification (using hybrid AVA>1.0 cm 2 cut-point value) and AVCS (P = 0.502, log-rank test).
AVCS, aortic valve calcification score.
TAVI in patients with low valve calcification stroke or myocardial infarction and with 1-year mortality following TAVI. Staubach et al. 33 examined 1365 patients that underwent TAVI in a German registry and found similar device success rate and short term mortality between patients with severe AVC compared to mild or moderate AVC. However, in their study, the amount of aortic calcification was determined by visual estimation by each investigator, either by means of echocardiography or CT imaging. Among our 93 patients with low AVC there was 1 case of 30-day mortality (from sepsis) and the 30-day rates of major complications were similar to patients with higher AVCS. Encouragingly, the overall mid-term mortality was also similar between groups. Interestingly, a sub-group analysis demonstrated better outcome in patients with low AVCS and high aortic valve gradients, and worst outcome for patients with high AVCS and LG.
Our results suggest that utilization of the hybrid (CT-echo) AVA > 1.0 cm 2 yields to over-reclassification of AS severity to moderate class. Indeed with this cut-point, a large proportion of patients with high gradient, undoubtedly severe AS were reclassified to moderate AS. The utilization of a larger cut-point (>1.2 cm 2 ) as proposed by Clavel et al. 15 resulted in less over-reclassification but still a significant proportion of patients with high gradient were re-classified to moderate. Furthermore, patients reclassified to moderate AS on the basis of the hybrid AVA had excellent outcome after TAVR, even if they had low AVCS and/or low gradient.
Study limitations
The main limitations of the present study are that it represents a retrospective, single-center experience using only balloonexpandable valves. Our clinical outcome results may therefore not be applicable to other valve types. Moreover, due to the number of patients and small number of events there was lack of statistical power to assess several 30-day clinical outcome variables such as valve embolization and the effect of low AVCS on mid-term mortality. Nonetheless, previous studies that examined the correlation between AVC and procedural outcome did not focus on these unique patients in whom mild degree of AVC can potentially result in valve dislodgment. Future studies with larger number of patients, longer follow-up and uzse of different valve types including self-expandable devices may further clarify this subject. Another main limitation is that all patients in the present cohort underwent TAVI and not surgical valve replacement, and therefore we could not examine potential pathological mechanisms causing severe AS in patients with low AVCS. Notwithstanding, the present study focused on a significant subset of patients with severe AS despite lack of substantial calcification that should be further investigated and characterized in future studies.
Conclusions
Patients with severe AS and low AVC were found to be younger and to have a higher BMI. Balloon-expandable TAVI in patients with a mildly calcified aortic valve was not associated with increased risk of valve embolization. We demonstrated high device success and lower rates of PVR for these patients. Furthermore, these patients had similar survival compared to patients with high ACVS. These findings suggest that in patients with evidence of haemodynamically severe AS at echocardiography, the presence of low ACVS at CT and/or moderate hybrid (CT-echocardiographic) AVA should not preclude the consideration of balloon-expandable TAVI.
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